FDA issues alert about HIV drug Prezista

Mar 24, 2008

The U.S. Food and Drug Administration has issued an alert concerning reports of liver injury in patients taking Prezista.

The FDA said Prezista (darunavir), an anti-retroviral drug used to treat for the human immunodeficiency virus HIV, is suspected of contributing to several hepatic events, including liver failure, destruction of liver tissue, cirrhosis, hepatitis and jaundice.

Healthcare professionals were advised to conduct appropriate laboratory testing prior to and after starting patients on Prezista and to be alert for symptoms of hepatotoxicity, including unexplained fatigue, anorexia, nausea, jaundice, dark urine and liver tenderness.

Patients with chronic hepatitis B or C or those who have pretreatment elevations of liver function tests should be monitored more frequently.

The FDA said it worked with the drug's manufacturer -- Tibotec Therapeutics Inc. of Bridgewater, N.J. -- to include the new hepatotoxicity information on the drug's label.

Copyright 2008 by United Press International

Explore further: Intimacy a strong motivator for PrEP HIV prevention

add to favorites email to friend print save as pdf

Related Stories

Mexico acid leak leaves orange river, toxic water

18 hours ago

Ramona Yesenia stood in her town square with two empty jugs, waiting for water to replace the municipal supply contaminated by a chemical spill that turned Mexico's Sonora river orange.

Recommended for you

Intimacy a strong motivator for PrEP HIV prevention

19 hours ago

Men in steady same-sex relationships where both partners are HIV negative will often forgo condoms out of a desire to preserve intimacy, even if they also have sex outside the relationship. But the risk of ...

UNL sociologist studies HIV spread in rural Puerto Rico

Aug 14, 2014

Puerto Rico has one of the highest HIV rates in the United States, primarily from drug users sharing needles. To help prevent HIV infections, a University of Nebraska-Lincoln sociologist is using his expertise ...

User comments : 0